Key result
Treatment with an adenoviral vector encoding human HGF gene significantly mitigated left ventricular dilatation, dysfunction, cardiomyocyte atrophy, and myocardial fibrosis in mice.
Why the study?
Does HGF gene delivery mitigate cardiac dysfunction in mice with doxorubicin-induced cardiomyopathy?
Does HGF gene delivery mitigate cardiac dysfunction in mice with doxorubicin-induced cardiomyopathy?
HGF gene delivery mitigates established cardiac dysfunction, cardiomyocyte atrophy, and fibrosis in a mouse model of doxorubicin-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
HGF gene delivery mitigates doxorubicin cardiomyopathy in mice; leaves open translation to human heart failure therapy.
Esaki et al. (2007) studied Doxorubicin-induced cardiomyopathy. Adenoviral vector encoding human HGF gene (Ad.CAG-HGF) vs. LacZ gene was evaluated on Left ventricular dilatation and dysfunction, cardiomyocyte atrophy/degeneration, and myocardial fibrosis. Treatment with an adenoviral vector encoding human HGF gene significantly mitigated left ventricular dilatation, dysfunction, cardiomyocyte atrophy, and myocardial fibrosis in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: